SF and MD have no conflicts to declare. DG has received

funding to support a PhD studentship from Wyeth Pharmaceuticals. SCC currently receives unrestricted research funding from Pfizer Vaccines (previously Wyeth Vaccines). JMJ and SCC have received consulting fees from GlaxoSmithKline and have received financial assistance from vaccine manufacturers to attend conferences. All grants and honoraria are paid into accounts within the respective NHS Trusts or Universities, or to independent charities. JMJ, TJM, SCC, AS and GFSE C59 wnt clinical trial previously received funding from Wyeth Pharmaceuticals for a collaborative project with the Institute of Biological Sciences, University of Glasgow and the Scottish Meningococcal and Pneumococcal Reference Laboratory (2005–2007). BD, JM and EM have no conflicts to declare. CR has received research funding from and has acted as a consultant for Wyeth Pharmaceuticals. “
“The strong cellular immune responses induced by viral vectors have encouraged their clinical development as candidate vaccines against cancer and a number of intracellular pathogens, notably

pre-erythrocytic infection by Plasmodia, Mycobacterium tuberculosis (TB) and HIV-1 http://www.selleckchem.com/products/pfi-2.html [1]. Recombinant protein-in-adjuvant formulations have remained predominant in efforts to induce antibody responses against extracellular pathogens, including blood-stage Etomidate malaria parasites [2]. Recently, replication-deficient viral-vectored vaccines encoding blood-stage malaria antigens have, like protein vaccines, proven protective in a rodent malaria model and induced promising in vitro activity in assays against Plasmodium falciparum [3], [4], [5] and [6]. Combined

cellular and humoral responses may be desirable for maximal immune-mediated protective efficacy in a number of contexts, notably against malaria (both pre-erythrocytic and blood-stage) and HIV [6], [7], [8] and [9]. Despite the ongoing development of single antigen, single formulation vaccines many speculate that the first highly efficacious vaccine against P. falciparum malaria will require a multi-antigen, multi-stage, or multi-formulation product [7]. Multiple strategies using heterologous prime-boost combinations of DNA, viral vectored and protein vaccines have demonstrated capacity to induce combined antibody and cellular responses in the HIV field. Adenovirus prime–protein boost regimes induce greatly enhanced antibody immunogenicity compared to individual adenovirus or protein/adjuvant immunization, both in guinea pigs and primates [10] and [11]. Similarly, replication-competent-adenovirus prime–protein boost and triple platform DNA-Semliki Forest virus–orthopoxvirus combinations have proven immunogenic and protective in a macaque SIV model [12] and [13].